A breaking update regarding India's vaccination strategy reveals that the government of India has finalized an advance arrangement with Biological-E Ltd., for 30 crore COVID vaccine doses. The Union Ministry of Health has finalized an advance of Rs 1,500 crore with Hyderabad-based pharmaceutical company Biological E for the manufacture of 30 crore Covid-19 vaccines. In April, the company received the nod from the Central Drugs and Standards Control Organisation (CDSCO) to conduct phase 3 clinical trials on its COVID vaccine candidate, which has been developed in association with Baylor College of Medicine, US, and is modelled after the Hepatitis E vaccine. TIMES NOW's Sherine Elizabeth brings the details.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting